ANVS · Annovis Bio, Inc.
$1.72
+0.03 (+1.83%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$73.28M
Shares
42.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.69
Open$1.73
Day$1.67–1.73
52W close$1.59–5.10
Avg vol 30d559K
Short int5.0M · 11.7% float · 8.2d
Short vol59%
Last earningsAug 12, 2025
DataJan 2020–Sep 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$49.52M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$18.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+92.5%
Year over year · more shares
Price change (1Y)
-26.8%
Trailing year
Short interest
11.7%
Latest settlement · 8.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−6%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
3%
near low
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−32%
trailing
YTD return
−51%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.65% of float · ▼ -4.4% MoM · 8.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.65% of float · ▼ -4.4% MoM · 8.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 3%
Range high $5
vs 200-day avg -32%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANVS
this stock
Annovis Bio, Inc.
|
$73.28M | -51.2% | — | — | 11.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +6.7% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANVS | -7.1% | -9.6% | -32.4% | -1.7% | -51.2% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -6.6% | -8.4% | -45.0% | -1.1% | -62.9% |
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
51 filings
51 filers
Visit website
Investor relations